Improvement of psychiatric symptoms and social function of aripiprazole long acting injection for outpatient schizophrenia

Improvement of psychiatric symptoms and social function of aripiprazole long acting injection for outpatient schizophrenia - Improvement of psychiatric symptoms and social function of aripiprazole long acting injection for outpatient schizophrenia

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041120

Enrollment

140

Registered

2020-07-16

Start date

2020-08-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: A patient with schizophrenia who has been treated with aripiprazole LAI for more than 1 year between May 2015 and April 2020 at Naomasa Clinic.

Exclusion criteria

Exclusion criteria: Patients who do not meet the above selection criteria.

Design outcomes

Primary

Measure	Time frame
For patients who have been treated with aripiprazole LAI for more than 1 year from May 2015 to July 2020, the social function before and after switching from the previous drug will be evaluated by SOFAS according to the patient background.	—

Secondary

Measure	Time frame
The improvement of psychotic symptoms is also evaluated by CGI-I. Treatment continuation rate. Timing of improvement depending on the number of doses	—

Countries

Japan

Contacts

Public ContactTetsushi Naomasa

Sanzyukai Medical Corporation Naomasa Clinic

eye_ve4n.thatmovie_2@icloud.com098-989-9229

Outcome results